1-20 of 471
drug combinations
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, MS, Nicola Long, Anupriya Agarwal, PhD, Cristina E. Tognon, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner
Journal: Blood
Blood (2019) 134 (Supplement_1): 878.
https://doi.org/10.1182/blood-2019-126020
Published: 2019
Journal Articles

Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating Perp gene In Vivo and in Vitro

Qing Li, MD, Yunfan Yang, MD, Yu Wu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 536.
https://doi.org/10.1182/blood-2019-123876
Published: 2019
Journal Articles

Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication

Y. Lynn Lynn Wang, MD PhD, Carrie Franzen, PhD, Shengchun Wang, MD PhD, Girish Venkataraman, MD MBBS, Lei Li, MS, Nifang Niu, PhD, Madina Sukhanova, PhD, Yifan Tu, MD PhD, Juehua Gao, MD PhD, Yi-Hua Chen, MD, Shuo Ma, MD PhD, Richard A. Larson, MD, Lu Pin, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 475.
https://doi.org/10.1182/blood-2019-125396
Published: 2019
Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Pamela S. Becker, MD PhD, Vivian G. Oehler, MD, Carl Anthony Blau, MD, Timothy S Martins, PhD, Niall Curley, Sylvia Chien, Jin Dai, PhD, Nicole Kauer, Ka Yee Yeung, PhD, Ling-Hong Hung, PhD, Cody Hammer, Paul C. Hendrie, MD PhD, Mary-Elizabeth M. Percival, MD, Ryan D. Cassaday, MD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Kelda Gardner, PA-C, Mary Gwin, Heather Smith, PA-C, Andrew Carson, PhD, Bradley Patay, MD, Elihu H. Estey, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1269.
https://doi.org/10.1182/blood-2019-130996
Published: 2019
Journal Articles

PI3Kδ Inhibition Enhances Sensitivity of Primary High-Risk Childhood B-Cell Acute Lymphoblastic Leukemia Cells to Glucocorticoid Chemotherapy

Jessica A.O. Zimmerman, MD, Mimi Fang, Arunkumar Modi, MBBS, MPH, Adam Dupuy, PhD, Sarah K. Tasian, MD, Miles A. Pufall, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2572.
https://doi.org/10.1182/blood-2019-129205
Published: 2019
Journal Articles

PKR-like Endoplasmic Reticulum Kinase Mediates Apoptosis Induced By Pharmacological AMP-Activated Protein Kinase Activation in Acute Myeloid Leukemia

Laury Poulain, PhD, Adrien Grenier, MD PhD, Johanna Mondesir, MD, Arnaud Jacquel, PhD, Claudie Bosc, Lucille Stuani, PhD, Rudy Birsen, MD, Sarah Mouche, Justine Decroocq, MD, Fetta Mazed, PhD, Benoit Viollet, PhD, Patrick Auberger, PhD, Pierre Sujobert, MD PhD, Didier Bouscary, MD PhD, Jean-Emmanuel Sarry, PhD, Jerome Tamburini, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2552.
https://doi.org/10.1182/blood-2019-123364
Published: 2019
Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2574.
https://doi.org/10.1182/blood-2019-123287
Published: 2019
Journal Articles

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Sean M Post, PhD, Huaxian Ma, MS, Vivian Ruvolo, Xiaorui Zhang, BS, Tomoko Yasuhiro, Kohei Tanaka, Ryohei Kozaki, Toshio Yoshizawa, PhD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Marina Y Konopleva, MD PhD, Steven M. Kornblau, MD, Joseph D. Khoury, MD, Michael Andreeff, MD PhD, Peter P. Ruvolo, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2550.
https://doi.org/10.1182/blood-2019-128626
Published: 2019
Journal Articles

Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma

Maria Gkotzamanidou, MD PhD, Vassilis L. Souliotis, PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2528.
https://doi.org/10.1182/blood-2019-123338
Published: 2019
Journal Articles

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Ruiqi Zhu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Amy S. Duffield, MD PhD, Donald Small, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2564.
https://doi.org/10.1182/blood-2019-131635
Published: 2019
Journal Articles

Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells

Mohammad Hojjat-Farsangi, MSc,PhD, Amineh Ghaderi, MSc, AmirHossein Daneshmanesh, MD PhD, Jemina Lehto, MSc, Ali Moshfegh, MSc,PhD, Parviz Kokhaei, MSc,PhD, Jan Vågberg, MSc,PhD, Elisabeth Olsson, MSc,PhD, Charlotta Löfberg, MSc,PhD, Charlotta Carina Norström, MSc,PhD, Johan Schultz, MSc,PhD, Martin Norin, MSc,PhD, Thomas Olin, MSc,PhD, Elias Drakos, MD PhD Prof., George Z. Rassidakis, MD PhD Prof., Anders Österborg, MD PhD, Håkan Mellstedt, MD PhD Prof.
Journal: Blood
Blood (2019) 134 (Supplement_1): 2565.
https://doi.org/10.1182/blood-2019-126801
Published: 2019
Journal Articles

BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML

Joseph M Brandwein, MD, Asmaa Basonbul, MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 2646.
https://doi.org/10.1182/blood-2019-129529
Published: 2019
Journal Articles

Quantitative Proteomic Analysis of Relapsed Multiple Myeloma Identifies CDK6 Upregulation As a Potential Targetable Resistance Mechanism for Lenalidomide

Yuen Lam Dora Ng, Stephan Bohl, Evelyn Ramberger, Oliver Popp, Imke Bauhuf, Anna Dolnik, Christian Steinebach, Michael Gütschow, Lars Bullinger, Philipp Mertins, Jan Kroenke
Journal: Blood
Blood (2019) 134 (Supplement_1): 2567.
https://doi.org/10.1182/blood-2019-130682
Published: 2019
Journal Articles

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

Anthony Quagliano, BS, Anilkumar Gopalakrishnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 2628.
https://doi.org/10.1182/blood-2019-129198
Published: 2019
Journal Articles

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Fei Huang, Ronald Hoffman, MD, Xiaoli Wang, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2963.
https://doi.org/10.1182/blood-2019-126189
Published: 2019
Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3052.
https://doi.org/10.1182/blood-2019-130807
Published: 2019
Journal Articles

Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition

Nadine Abdallah, MD, S. Vincent Rajkumar, MD, Dragan Jevremovic, MD PhD, Prashant Kapoor, MD, Angela Dispenzieri, MD, Morie A. Gertz, MD, Martha Q. Lacy, MD, Francis K. Buadi, MB, CHB, Suzanne R. Hayman, MD, David Dingli, MD PhD, Eli Muchtar, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Rahma M Warsame, MD, Mustaqeem A. Siddiqui, MDMBA, Ronald S. Go, MD, Nelson Leung, MD, Yi L. Hwa, APRN, CNP, DNP, Miriam A. Hobbs, APRN, CNP, DNP, Amie Fonder, PA-C, MS, Robert A. Kyle, MD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3080.
https://doi.org/10.1182/blood-2019-131835
Published: 2019
Journal Articles

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Mark Roschewski, MD, Raquel Izumi, PhD, Ahmed Hamdy, MD, Manish R. Patel, MD, Hendrik-Tobias Arkenau, MD PhD, Sven de Vos, MD PhD, Patrick M Reagan, MD, Pier Luigi Zinzani, MD PhD, Andrew Davies, MD PhD, John M Pagel, MD PhD, Julie M Vose, MDMBA, Bojena Bitman, Graham Brock, PhD, Edwin Clark, PhD, Melanie M. Frigault, PhD, Joseph Ware, PhD, Buyue Yang, MD PhD, Wyndham Wilson, MD, Louis Staudt, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2869.
https://doi.org/10.1182/blood-2019-125939
Published: 2019
Journal Articles

Ex Vivo Drug Sensitivity Screens Identify Personalized Treatment Options for CLL Patients

Sigrid Strand Skånland, PhD, Bendiksen Henrik, MSc, Andrea Cremaschi, PhD, Deepak Balaji Thimiri Govinda Raj, PhD, Ludvig Andre Munthe, MD PhD, Geir Erland Tjønnfjord, MD PhD, Kjetil Taskén, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5446.
https://doi.org/10.1182/blood-2019-121890
Published: 2019
Journal Articles

Efficacy and Toxicity of Lenalidomide for Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Sravanthi Kotapati, MBBS, Insija Ilyas Selene, MBBS, Madeeha Shafqat, Syeda Fatima Hassan, MBBS, Zunairah Shah, MBBS, Arshia Akbar, MD, Owais ur Rehman, MBBS, Tariq Iqtidar Sadiq Syed, MD, Marium Ghani, MBBS, Syed Maaz Abdullah, MBBS, Maimoona Khan, MBBS, Jemin Aby Jose, MD, Faiz Anwer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5488.
https://doi.org/10.1182/blood-2019-129733
Published: 2019